PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation

Richard W Joseph, Sherri Z. Millis, Estrella M. Carballido, David Bryant, Zoran Gatalica, Sandeep Reddy, Alan H Bryce, Nicholas J. Vogelzang, Melissa L. Stanton, Erik P Castle, Thai H Ho

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Monoclonal antibodies that target the programmed death-1 (PD-1)-programmed death ligand-1 (PD-L1) axis have antitumor activity against multiple cancers. The presence of sarco-matoid differentiation in renal cell carcinoma (RCC) is associated with resistance to targeted therapy and poor responses to IL2 immunotherapy. Given the aggressive nature of RCC with sarco-matoid differentiation and the exclusion of sarcomatoid histology from metastatic RCC clinical trials, less is understood regarding selection of therapies. Here, we characterized the PD-1/PD-L1 axis in RCC with sarcomatoid differentiation. We directly compared two PD-L1 antibodies and found concordance of PD-L1 positivity in 89% of tested RCCs with sarcomatoid differentiation. Coexpression of PD-L1 on neoplastic cells and the presence of PD-1-positive tumor-infiltrating lymphocytes were identified in 50% (13 of 26) of RCCs with sarcomatoid differentiation. In contrast, only 1 of 29 clear cell RCCs (3%) had concurrent expression of PD-L1 and PD-1 (P = 0.002). Our study suggests that RCC with sarcomatoid differentiation may express PD-1/PD-L1 at a higher percentage than RCC without sarcomatoid differentiation, and patients with these tumors may be good candidates for treatment with anti-PD-1/PD-L1 therapies.

Original languageEnglish (US)
Pages (from-to)1303-1307
Number of pages5
JournalCancer immunology research
Volume3
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Renal Cell Carcinoma
Ligands
Tumor-Infiltrating Lymphocytes
Therapeutics
Immunotherapy
Interleukin-2
Neoplasms
Histology
Monoclonal Antibodies
Clinical Trials

ASJC Scopus subject areas

  • Cancer Research
  • Immunology

Cite this

PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation. / Joseph, Richard W; Millis, Sherri Z.; Carballido, Estrella M.; Bryant, David; Gatalica, Zoran; Reddy, Sandeep; Bryce, Alan H; Vogelzang, Nicholas J.; Stanton, Melissa L.; Castle, Erik P; Ho, Thai H.

In: Cancer immunology research, Vol. 3, No. 12, 01.12.2015, p. 1303-1307.

Research output: Contribution to journalArticle

Joseph, RW, Millis, SZ, Carballido, EM, Bryant, D, Gatalica, Z, Reddy, S, Bryce, AH, Vogelzang, NJ, Stanton, ML, Castle, EP & Ho, TH 2015, 'PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation', Cancer immunology research, vol. 3, no. 12, pp. 1303-1307. https://doi.org/10.1158/2326-6066.CIR-15-0150
Joseph, Richard W ; Millis, Sherri Z. ; Carballido, Estrella M. ; Bryant, David ; Gatalica, Zoran ; Reddy, Sandeep ; Bryce, Alan H ; Vogelzang, Nicholas J. ; Stanton, Melissa L. ; Castle, Erik P ; Ho, Thai H. / PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation. In: Cancer immunology research. 2015 ; Vol. 3, No. 12. pp. 1303-1307.
@article{de3b3c261cd04938b9bab9353d1aba19,
title = "PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation",
abstract = "Monoclonal antibodies that target the programmed death-1 (PD-1)-programmed death ligand-1 (PD-L1) axis have antitumor activity against multiple cancers. The presence of sarco-matoid differentiation in renal cell carcinoma (RCC) is associated with resistance to targeted therapy and poor responses to IL2 immunotherapy. Given the aggressive nature of RCC with sarco-matoid differentiation and the exclusion of sarcomatoid histology from metastatic RCC clinical trials, less is understood regarding selection of therapies. Here, we characterized the PD-1/PD-L1 axis in RCC with sarcomatoid differentiation. We directly compared two PD-L1 antibodies and found concordance of PD-L1 positivity in 89{\%} of tested RCCs with sarcomatoid differentiation. Coexpression of PD-L1 on neoplastic cells and the presence of PD-1-positive tumor-infiltrating lymphocytes were identified in 50{\%} (13 of 26) of RCCs with sarcomatoid differentiation. In contrast, only 1 of 29 clear cell RCCs (3{\%}) had concurrent expression of PD-L1 and PD-1 (P = 0.002). Our study suggests that RCC with sarcomatoid differentiation may express PD-1/PD-L1 at a higher percentage than RCC without sarcomatoid differentiation, and patients with these tumors may be good candidates for treatment with anti-PD-1/PD-L1 therapies.",
author = "Joseph, {Richard W} and Millis, {Sherri Z.} and Carballido, {Estrella M.} and David Bryant and Zoran Gatalica and Sandeep Reddy and Bryce, {Alan H} and Vogelzang, {Nicholas J.} and Stanton, {Melissa L.} and Castle, {Erik P} and Ho, {Thai H}",
year = "2015",
month = "12",
day = "1",
doi = "10.1158/2326-6066.CIR-15-0150",
language = "English (US)",
volume = "3",
pages = "1303--1307",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation

AU - Joseph, Richard W

AU - Millis, Sherri Z.

AU - Carballido, Estrella M.

AU - Bryant, David

AU - Gatalica, Zoran

AU - Reddy, Sandeep

AU - Bryce, Alan H

AU - Vogelzang, Nicholas J.

AU - Stanton, Melissa L.

AU - Castle, Erik P

AU - Ho, Thai H

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Monoclonal antibodies that target the programmed death-1 (PD-1)-programmed death ligand-1 (PD-L1) axis have antitumor activity against multiple cancers. The presence of sarco-matoid differentiation in renal cell carcinoma (RCC) is associated with resistance to targeted therapy and poor responses to IL2 immunotherapy. Given the aggressive nature of RCC with sarco-matoid differentiation and the exclusion of sarcomatoid histology from metastatic RCC clinical trials, less is understood regarding selection of therapies. Here, we characterized the PD-1/PD-L1 axis in RCC with sarcomatoid differentiation. We directly compared two PD-L1 antibodies and found concordance of PD-L1 positivity in 89% of tested RCCs with sarcomatoid differentiation. Coexpression of PD-L1 on neoplastic cells and the presence of PD-1-positive tumor-infiltrating lymphocytes were identified in 50% (13 of 26) of RCCs with sarcomatoid differentiation. In contrast, only 1 of 29 clear cell RCCs (3%) had concurrent expression of PD-L1 and PD-1 (P = 0.002). Our study suggests that RCC with sarcomatoid differentiation may express PD-1/PD-L1 at a higher percentage than RCC without sarcomatoid differentiation, and patients with these tumors may be good candidates for treatment with anti-PD-1/PD-L1 therapies.

AB - Monoclonal antibodies that target the programmed death-1 (PD-1)-programmed death ligand-1 (PD-L1) axis have antitumor activity against multiple cancers. The presence of sarco-matoid differentiation in renal cell carcinoma (RCC) is associated with resistance to targeted therapy and poor responses to IL2 immunotherapy. Given the aggressive nature of RCC with sarco-matoid differentiation and the exclusion of sarcomatoid histology from metastatic RCC clinical trials, less is understood regarding selection of therapies. Here, we characterized the PD-1/PD-L1 axis in RCC with sarcomatoid differentiation. We directly compared two PD-L1 antibodies and found concordance of PD-L1 positivity in 89% of tested RCCs with sarcomatoid differentiation. Coexpression of PD-L1 on neoplastic cells and the presence of PD-1-positive tumor-infiltrating lymphocytes were identified in 50% (13 of 26) of RCCs with sarcomatoid differentiation. In contrast, only 1 of 29 clear cell RCCs (3%) had concurrent expression of PD-L1 and PD-1 (P = 0.002). Our study suggests that RCC with sarcomatoid differentiation may express PD-1/PD-L1 at a higher percentage than RCC without sarcomatoid differentiation, and patients with these tumors may be good candidates for treatment with anti-PD-1/PD-L1 therapies.

UR - http://www.scopus.com/inward/record.url?scp=84962052183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962052183&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-15-0150

DO - 10.1158/2326-6066.CIR-15-0150

M3 - Article

C2 - 26307625

AN - SCOPUS:84962052183

VL - 3

SP - 1303

EP - 1307

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 12

ER -